Advertisement

Der Chirurg

, Volume 90, Issue 4, pp 279–286 | Cite as

Bewertung der individualisierten Therapie des Rektumkarzinoms

  • F. AignerEmail author
  • A. Lorenz
  • D. Öfner
  • J. Pratschke
Leitthema
  • 164 Downloads

Zusammenfassung

Bei der Bewertung einer speziellen Operationstechnik oder einer bestimmten Behandlungsstrategie nach genau definierten Qualitätskriterien oder -indikatoren spielt die individualisierte und maßgeschneiderte Therapie eine wichtige Rolle, da hier Abweichungen von generellen Empfehlungen, wie in Leitlinien definiert, genauestens begründet, dokumentiert und evaluiert werden müssen. Ziel dieses Leitthemenartikels ist es daher, die individualisierte Therapie des Rektumkarzinoms dahingehend anhand der vorliegenden Evidenz zu prüfen und im Kontext des Behandlungsalgorithmus bestehender Leitlinien zu diskutieren. Neben einer Literaturrecherche wurde die aktualisierte deutsche S3-Leitlinie zum kolorektalen Karzinom als Basis herangezogen. Gerade beim Rektumkarzinom des mittleren und unteren Drittels sind von der Vorbehandlung, der eigentlichen Operation bis hin zur Nachbehandlung und Nachsorge individuelle, patienten- und tumorbezogene Parameter bei der interdisziplinären Entscheidungsfindung zur optimalen Therapie von wegweisender Bedeutung.

Schlüsselwörter

Qualitätsindikatoren Interdisziplinarität Metastasierung S3-Leitlinie Radiochemotherapie 

Assessment of individualized treatment of rectal carcinoma

Abstract

Individualized and tailored treatment plays a crucial role in the rating of special operation techniques or certain treatment strategies following defined quality criteria and indicators. Deviations from clearly defined recommendations in guidelines must therefore be justified, documented and evaluated as precisely as possible. The aim of this leading article is to examine the individualized treatment of rectal cancer based on existing evidence and to discuss its role in the light of routinely used treatment algorithms. In addition to a web-based literature search the current German national S3 guidelines on colorectal cancer were also included. In the treatment of cancer in the middle and lower third of the rectum, individual, patient and tumor-related parameters are of decisive importance from the pretreatment stage to the actual surgery up to aftercare and adjuvant therapy to enable interdisciplinary decision making for optimal treatment.

Keywords

Quality indicators Interdisciplinarity Metastasis S3 guidelines Chemoradiotherapy 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

F. Aigner, A. Lorenz, D. Öfner und J. Pratschke geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Adamina M, Buchs NC, Penna M, Hompes R, St.Gallen Colorectal Consensus Expert Group (2018) St.Gallen consensus on safe implementation of transanal total mesorectal excision. Surg Endosc 32(3):1091–1103CrossRefGoogle Scholar
  2. 2.
    Armbruster M, D’Anastasi M, Holzner V, Kreis ME, Dietrich O, Brandlhuber B, Graser A, Brandlhuber M (2018) Improved detection of a tumorous involvement of the mesorectal fascia and locoregional lymph nodes in locally advanced rectal cancer using DCE-MRI. Int J Colorectal Dis 33(7):901–909CrossRefGoogle Scholar
  3. 3.
    Cerantola Y, Grass F, Cristaudi A, Demartines N, Schäfer M, Hübner M (2011) Perioperative nutrition in abdominal surgery: recommendations and reality. Gastroenterol Res Pract 2011:739347CrossRefGoogle Scholar
  4. 4.
    Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL, Daniels IR, Smart NJ, Osborne ME, Beets GL, Maas M, Bitterman DS, Du K, Gollins S, Myint SA, Smith FM, Saunders MP, Scott N, O’Dwyer ST, de Castro Araujo RO, Valadao M, Lopes A, Hsiao CW, Lai CL, Smith RK, Paulson EC, Appelt A, Jakobsen A, Wexner SD, Habr-Gama A, Sao Julião G, Perez R, Renehan AG (2018) Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol 3(12):825–836CrossRefGoogle Scholar
  5. 5.
    Conrad C, Vauthey JN, Masayuki O, Sheth RA, Yamashita S, Passot G, Bailey CE, Zorzi D, Kopetz S, Aloia TA, You YN (2017) Individualized treatment sequencing selection contributes to optimized survival in patients with rectal cancer and synchronous liver metastases. Ann Surg Oncol 24(13):3857–3864CrossRefGoogle Scholar
  6. 6.
    Deijen CL, Velthuis S, Tsai A, Mavroveli S, de Lange-de Klerk ES, Sietses C, Tuynman JB, Lacy AM, Hanna GB, Bonjer HJ (2016) COLOR III: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer. Surg Endosc 30(8):3210–3215CrossRefGoogle Scholar
  7. 7.
    Detering R, Borstlap WAA, Broeders L, Hermus L, Marijnen CAM, Beets-Tan RGH, Bemelman WA, van Westreenen HL, Tanis PJ, Dutch Snapshot Research Group (2018) Cross-sectional study on MRI restaging after chemoradiotherapy and interval to surgery in rectal cancer: influence on short- and long-term outcomes. Ann Surg Oncol 13.  https://doi.org/10.1245/s10434-018-07097-7 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Dominguez-Vigil IG, Moreno-Martinez AK, Wang JY, Roehrl MHA, Barrera-Saldana HA (2018) The dawn of the liquid biopsy in the fight against cancer. Oncotarget 9:2912–2922CrossRefGoogle Scholar
  9. 9.
    Dossa F, Chesney TR, Acuna SA, Baxter NN (2017) A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2(7):501–513CrossRefGoogle Scholar
  10. 10.
    Dutta SW, Alonso CE, Jones TC, Waddle MR, Janowski EM, Trifiletti DM (2018) Short-course versus long-course neoadjuvant therapy for non-metastatic rectal cancer: patterns of care and outcomes from the national cancer database. Clin Colorectal Cancer 17(4):297–306CrossRefGoogle Scholar
  11. 11.
    Erlandsson J, Holm T, Pettersson D, Berglund Å, Cedermark B, Radu C, Johansson H, Machado M, Hjern F, Hallböök O, Syk I, Glimelius B, Martling A (2017) Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 18(3):336–346CrossRefGoogle Scholar
  12. 12.
    Grass JK, Perez DR, Izbicki JR, Reeh M (2018) Systematic review analysis of robotic and transanal approaches in TME surgery—A systematic review of the current literature in regard to challenges in rectal cancer surgery. Eur J Surg Oncol.  https://doi.org/10.1016/j.ejso.2018.11.010 CrossRefPubMedGoogle Scholar
  13. 13.
    Habr-Gama A, São Julião GP, Vailati BB, Castro I, Raffaele D (2017) Management of the complete clinical response. Clin Colon Rectal Surg 30(5):387–394CrossRefGoogle Scholar
  14. 14.
    Kim HJ, Choi GS, Park JS, Park SY, Yang CS, Lee HJ (2018) The impact of robotic surgery on quality of life, urinary and sexual function following total mesorectal excision for rectal cancer: a propensity score-matched analysis with laparoscopic surgery. Colorectal Dis 20(5):O103–O113CrossRefGoogle Scholar
  15. 15.
    Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Kolorektales Karzinom, Langversion 2.1, 2019, AWMF Registrierungsnummer: 021/007OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/kolorektales-karzinom/. Zugegriffen: 20. Jan. 2019Google Scholar
  16. 16.
    Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, Meunier B, Mehrdad J, Cotte E, Desrame J, Karoui M, Benoist S, Kirzin S, Berger A, Panis Y, Piessen G, Saudemont A, Prudhomme M, Peschaud F, Dubois A, Loriau J, Tuech JJ, Meurette G, Lupinacci R, Goasgen N, Parc Y, Simon T, Tiret E (2016) Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6). J Clin Oncol 34(31):3773–3780CrossRefGoogle Scholar
  17. 17.
    Mörgeli R, Scholtz K, Kurth J, Treskatsch S, Neuner B, Koch S, Kaufner L, Spies C (2017) Perioperative management of elderly patients with gastrointestinal malignancies: the contribution of anesthesia. Visc Med 33:267–274CrossRefGoogle Scholar
  18. 18.
    Montroni I, Ugolini G, Saur NM, Spinelli A, Rostoft S, Millan M, Wolthuis A, Daniels IR, Hompes R, Penna M, Fürst A, Papamichael D, Desai AM, Cascinu S, Gèrard JP, Myint AS, Lemmens VEPP, Berho M, Lawler M, De Liguori Carino N, Potenti F, Nanni O, Altini M, Beets G, Rutten H, Winchester D (2018) Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. Wexner SD, Audisio RA. Eur J Surg Oncol 44(11):1685–1702CrossRefGoogle Scholar
  19. 19.
    Negoi I, Hostiuc S, Paun S, Negoi RI, Beuran M (2016) Extralevator vs conventional abdominoperineal resection for rectal cancer—A systematic review and meta-analysis. Am J Surg 212(3):511–526CrossRefGoogle Scholar
  20. 20.
    Park J, Danielsen AK, Angenete E, Bock D, Marinez AC, Haglind E, Jansen JE, Skullman S, Wedin A, Rosenberg J (2018) Quality of life in a randomized trial of early closure of temporary ileostomy after rectal resection for cancer (EASY trial). Br J Surg 105(3):244–251CrossRefGoogle Scholar
  21. 21.
    Pisarska M, Gajewska N, Małczak P, Wysocki M, Witowski J, Torbicz G, Major P, Mizera M, Dembiński M, Migaczewski M, Budzyński A, Pędziwiatr M (2018) Defunctioning ileostomy reduces leakage rate in rectal cancer surgery—systematic review and meta-analysis. Oncotarget 9(29):20816–20825CrossRefGoogle Scholar
  22. 22.
    Roodbeen SX, Penna M, Mackenzie H, Kusters M, Slater A, Jones OM, Lindsey I, Guy RJ, Cunningham C, Hompes R (2018) Transanal total mesorectal excision (TaTME) versus laparoscopic TME for MRI-defined low rectal cancer: a propensity score-matched analysis of oncological outcomes. Surg Endosc.  https://doi.org/10.1007/s00464-018-6530-4 CrossRefPubMedGoogle Scholar
  23. 23.
    Rullier E, Rouanet P, Tuech JJ, Valverde A, Lelong B, Rivoire M, Faucheron JL, Jafari M, Portier G, Meunier B, Sileznieff I, Prudhomme M, Marchal F, Pocard M, Pezet D, Rullier A, Vendrely V, Denost Q, Asselineau J, Doussau A (2017) Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet 390(10093):469–479CrossRefGoogle Scholar
  24. 24.
    Ruppert R, Junginger T, Ptok H, Strassburg J, Maurer CA, Brosi P, Sauer J, Baral J, Kreis M, Wollschlaeger D, Hermanek P, Merkel S, OCUM group (2018) Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial. Br J Surg 105(11):1519–1529CrossRefGoogle Scholar
  25. 25.
    Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rödel C (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30(16):1926–1933CrossRefGoogle Scholar
  26. 26.
    Sprenger T, Rothe H, Beissbarth T, Conradi LC, Kauffels A, Homayounfar K, Behnes CL, Rödel C, Liersch T, Ghadimi M (2016) Lymphknotenmetastasen beim ypT1/2-Rektumkarzinom nach neoadjuvanter Radiochemotherapie. Die Achillesferse organerhaltender Operationsverfahren? Chirurg 87(7):593–601CrossRefGoogle Scholar
  27. 27.
    Stijns RCH, de Graaf EJR, Punt CJA, Nagtegaal ID, Nuyttens JJME, van Meerten E, Tanis PJ, de Hingh IHJT, van der Schelling GP, Acherman Y, Leijtens JWA, Bremers AJA, Beets GL, Hoff C, Verhoef C, Marijnen CAM, de Wilt JHW, CARTS Study Group (2018) Long-term oncological and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer: the CARTS study. Jama Surg.  https://doi.org/10.1001/jamasurg.2018.3752 CrossRefGoogle Scholar
  28. 28.
    Veltcamp Helbach M, Koedam TWA, Knol JJ, Velthuis S, Bonjer HJ, Tuynman JB, Sietses C (2018) Quality of life after rectal cancer surgery: differences between laparoscopic and transanal total mesorectal excision. Surg Endosc.  https://doi.org/10.1007/s00464-018-6276-z CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Chirurgische Klinik, Campus Virchow-Klinikum und MitteCharité Universitätsmedizin BerlinBerlinDeutschland
  2. 2.Universitätsklinik für Visceral‑, Transplantations- und ThoraxchirurgieMedizinische Universität InnsbruckInnsbruckÖsterreich

Personalised recommendations